Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13110 Neoplasms 10462 Carcinoma, Non-Small-Cell Lung 6857 Prostatic Neoplasms 6258 Colorectal Neoplasms 5925 Lung Neoplasms 5091 Multiple Myeloma 3568 Pancreatic Neoplasms 3552 Leukemia, Myeloid, Acute 3503 Neoplasm Metastasis 3499 Carcinoma, Hepatocellular 3264 Ovarian Neoplasms 3160 Melanoma 3134 Stomach Neoplasms 3051 Lymphoma 2981 Head and Neck Neoplasms 2595 Recurrence 2548 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496 Leukemia 2360 Colonic Neoplasms 2326 Brain Neoplasms 2306 Lymphoma, Non-Hodgkin 2265 Rectal Neoplasms 2186 Uterine Cervical Neoplasms 2182 Glioblastoma 2010 Leukemia, Lymphocytic, Chronic, B-Cell 1992 Carcinoma, Renal Cell 1910 Squamous Cell Carcinoma of Head and Neck 1875 Lymphoma, Follicular 1847 Esophageal Neoplasms 1797

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡